Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | FABP3 | P05413 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074609 | 1.00 | MEN1 (0.50) | MEN1KMT2ABLMADAM10ERBB2 | |
| SCHEMBL16056887 | 1.00 | MEN1 (0.50) | MEN1KMT2ABLMADAM10ERBB2 | |
| SCHEMBL5203561 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| SCHEMBL199462 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| SCHEMBL199461 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| SCHEMBL199463 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| SCHEMBL350996 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| SCHEMBL4780406 | 0.89 | SLC1A2 (0.47) | MEN1KMT2ABLMSLC1A2 | |
| Proline SCHEMBL7447947 | 0.88 | MEN1 (0.42) | MEN1KMT2ABLMADAM10ERBB2 | |
| Hydrochloric Acid SCHEMBL2297672 | 0.88 | SLC1A2 (0.46) | MEN1KMT2ABLMSLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2077719-B1 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | MEN1 3330/4885KMT2A 2789/4885BLM 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.